


DNAtrix
Biotechnology Research • San Diego, California, United States • 1-10 Employees
Company overview
| Headquarters | 10355 Science Center Drive, Suite 110, San Diego, CA 92121, US |
| Phone number | +125480000 |
| Websites | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Molecular Biology, Drug Development, Virology, Neuro-Oncology |
| Founded | 2005 |
| Employees | 1-10 |
| Socials |
Key Contact at DNAtrix
Joan Robbins
Vice President Translational Research
About DNAtrix
DNAtrix is a privately held biotech company developing virus-driven immunotherapies to treat cancer. Its proprietary adenovirus platform is based on an engineered version of the common cold virus that is designed to selectively infect and kill cancer cells while leaving healthy cells unharmed. The company’s lead product candidate is DNX-2401, which is expected to enter into a global pivotal Phase 3 clinical study for patients with recurrent glioblastoma. DNX-2401 is also being evaluated in a Phase 1 study for diffuse intrinsic pontine glioma, for which it has received FDA Fast Track and Rare Pediatric Disease designations. A second product candidate, DNX-2440, is entering a Phase 1 clinical study in patients with colorectal and other cancers with liver metastasis. The company’s investors include Morningside Ventures and Mercury Fund.
DNAtrix revenue & valuation
| Annual revenue | $6,000,000 |
| Revenue per employee | $2,000,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $19,200,000 |
| Total funding | $15,500,000 |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
DNAtrix Tech Stack
Discover the technologies and tools that power DNAtrix's digital infrastructure, from frameworks to analytics platforms.
CDN
Frequently asked questions
4.8
40,000 users



